GSK126, EZH2 methyltransferase inhibitor
Be the first to review this product! Submit a review
|
(2 Publications)
MW 526.7 Da. Potent inhibitor EZH2 methyltransferase inhibitor (Ki = 93 pM). Selective (>150-fold) versus EZH1. Greater than 1000-fold selective against a panel of 20 other human methyltransferases including both SET-domain-containing and non-SET-domain-containing methyltransferases. Decreases global H3K27me3 levels. Inhibits B-cell lymphoma cell proliferation in vitro. Inhibits EZH2 mutant tumor growth in xenograft models. Reactivates silenced PRC2 target genes and inhibits the proliferation of EZH2 mutant DLBCL cell lines and corresponding xenografts mice. Literature suggests that GSK126 is a potential treatment for EZH2 mutant lymphoma (McCabe et al).
View Alternative Names
AD 003, Alpha N-terminal protein methyltransferase 1A, C9orf32, CHET9, ChET 9 protein, Chromatin precipitated E2F target 9 protein, Chromosome 9 open reading frame 32, EED protein, EED, mouse, homolog of, EED_HUMAN, ENX-1, EZH2_HUMAN, EZH2b, Embryonic ECTODERM development protein homolog, Embryonic ectoderm development, Embryonic ectoderm development isoform a, Embryonic ectoderm development protein, mouse, homolog of, Enhancer of zeste 2, Enhancer of zeste homolog 2, Enhancer of zeste homolog 2 (Drosophila), Enhancer of zeste, Drosophila, homolog 2, Enx 1h, Histone-lysine N-methyltransferase EZH2, JJAZ1, Joined to JAZF1 protein, KIAA0160, KMT 6, KMT6A, Lysine N-methyltransferase 6, MGC9169, Methyltransferase like 11A, Methyltransferase-like protein 11A, N-terminal RCC1 methyltransferase, NRMT, NTM1A_HUMAN, NTMT1, OTTHUMP00000235483, OTTHUMP00000235484, OTTHUMP00000235485, Polycomb protein SUZ12, Polycomb protein eed, SUZ12 polycomb repressive complex 2 subunit, SUZ12_HUMAN, Suppressor of zeste 12 homolog, Suppressor of zeste 12 protein homolog, WAIT-1, WD protein associating with integrin cytoplasmic tails 1, WVS, WVS2, X-Pro-Lys N-terminal protein methyltransferase 1A, enhancer of zeste 2 polycomb repressive complex 2 subunit, hEED
- Chemical Structure
Lab
Chemical Structure - GSK126, EZH2 methyltransferase inhibitor (AB269816)
Chemical structure of GSK126, EZH2 methyltransferase inhibitor, 1346574-57-9
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling instructions
Need more advice on solubility, usage and handling? Please visit our our product support page for more details.
|
Refer to SDS for further information.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The PRC2 complex involving EZH2 EED and SUZ12 regulates gene expression by catalyzing the trimethylation of histone H3 on lysine 27 (H3K27me3) an important epigenetic marker for gene repression. The complex controls genes involved in development differentiation and proliferation. EZH2's activity is notably high in stem cells and proliferating cells due to its role in maintaining chromatin compaction and transcriptional silencing.
Pathways
The EZH2 protein and its associated PRC2 complex are elements of the epigenetic regulatory pathways controlling gene expression. They significantly impact the Wnt signaling pathway which influences embryonic development and cell growth. Additionally EZH2 interacts with other proteins such as histone deacetylases (HDACs) to facilitate tighter chromatin binding and gene silencing highlighting its role within the chromatin modification network.
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Heliyon 10:e32553 PubMed39183840
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed35955891
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com